Navigation Links
ViroPharma Announces Publication of Cinryze™ (C1 Esterase Inhibitor [Human]) Phase 3 Trial Results in Hereditary Angioedema (HAE) in the New England Journal of Medicine
Date:8/5/2010

completed, 88 subjects chose to enroll in an open-label extension study for the treatment of acute attacks. At a median of 11 months, 82 of the enrolled subjects had received open-label C1-inhibitor treatment for a total of 447 separate attacks, with the number of attacks per subject ranging from one to 57 (median 3). The median time to a response for the 447 attacks was 30 minutes, irrespective of whether a subject was given open-label treatment fewer than four times, four to nine times, or 10 times or more. The Kaplan–Meier estimate of the proportion of attacks that responded to treatment within four hours was 93 percent.

About Cinryze™ (C1 esterase inhibitor [human])

Cinryze is a highly purified, pasteurized and nanofiltered plasma-derived C1 esterase inhibitor product that has been approved by FDA for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE. C1 inhibitor therapy has been used acutely for more than 35 years in Europe in patients with C1 inhibitor deficiency.

The most common adverse reactions observed have been upper respiratory infection, sinusitis, rash and headache. No drug-related serious adverse events (SAEs) have been observed in clinical trials. Severe hypersensitivity reactions may occur. Thrombotic events have occurred in patients receiving high dose off-label C1 inhibitor therapy well above the approved treatment dosage regimen. Monitor patients with known risk factors for thrombotic events. With any blood or plasma derived product, there may be a risk of transmission of infectious agents, e.g. viruses and, theoretically, the CJD agent. The risk has been reduced by screening patients for prior exposure to certain virus infections and by manufacturing steps to reduce the risk of viral transmission including pasteurization and nanofiltration.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. ViroPharma to Present at Three Upcoming Healthcare Conferences
2. ViroPharma to Present at the Natixis Bleichroeder Conference
3. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
5. ViroPharma Announces Discontinuation of HCV-796 Development
6. ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
7. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
8. ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
9. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
10. ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
11. ViroPharma Incorporated Reports Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... --  Long Beach dentist , Dr. Rassouli, is now offering ... in tooth replacement because they offer the closest match to ... and preserve smiles and improve overall dental health. Dr. Rassouli ... as a part of a smile makeover or full mouth ... smile. The loss of a tooth can lead ...
(Date:11/22/2014)... Nov. 21, 2014  Particle Sciences, Inc (PSI), ... developed and manufactured a new innovative vaginal ring ... and Development arm of Exeltis Pharmaceuticals.  According to ... Management at Particle Sciences, "This vaginal ring was ... material sciences and modeling expertise.  We are thrilled ...
(Date:11/21/2014)... WALTHAM, Mass. , Nov. 21, 2014  Alere ... in rapid diagnostic tests, has appointed Juliet Cunningham ... created role, Cunningham will be responsible for driving communications ... to execute on a series of changes to increase ... our progress to investors," said Namal Nawana, Chief Executive ...
Breaking Medicine Technology:Long Beach Dentist, Dr. Rassouli, is Now Offering Dental Implants 2Particle Sciences' Clinical Trial Supplies Group Manufactures Innovative Vaginal Ring 2Alere Appoints Juliet Cunningham to Lead Investor Relations 2
... Mylan Inc. (Nasdaq: MYL ) today announced ... from the U.S. Food and Drug Administration (FDA) for its ... 50 mg and 100 mg, the generic version of Bayer,s ... exercise to improve glycemic control in adults with type 2 ...
... PRINCETON, N.J., Jan. 18, 2011 Soligenix, Inc. ... SNGX ), a late-stage biopharmaceutical company, announced ... of SGX202 (oral beclomathasone dipropionate or BDP) in ... The results indicate that dogs treated with SGX202 demonstrated ...
Cached Medicine Technology:Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury 2Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury 3Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury 4Soligenix Announces Positive Preliminary Results of SGX202 in Radiation Injury 5
(Date:11/23/2014)... November 23, 2014 The FDA is ... Common, **FDAnews On-Demand Webinar**, Dec. 11, 2014 ? Any ... The FDA’s focus on promotional activities is no longer ... Now they're looking at websites, Twitter, journal articles, TV ... for Thursday, Dec. 11, for On-Demand access to Timothy ...
(Date:11/23/2014)... Utah (PRWEB) November 23, 2014 ... insurance reimbursement for small businesses, announced their new ... The End of Employer-Provided Health Insurance. ... is the greatest financial risk facing most American ... U.S. employers, small and large, when it comes ...
(Date:11/22/2014)... PrettyTailor , an outstanding dress company, has recently updated ... buy new dresses at its online shop now. For ... As a matter of fact, PrettyTailor specializes in beautiful ... types of wedding outfits, including bridesmaid dresses, mother of ... provides a variety of occasion dresses, such as cocktail ...
(Date:11/22/2014)... BambooFlooringChina.com is a famous brand in ... its new collection of bamboo mats ; the new ... off. , According to the sales manager of ... it a highly renewable resource. Their bamboo mats are 100% ... which comes from natural bamboo with caramel bamboo strips. ...
(Date:11/22/2014)... Discount-Dress.com is an important company in the dress ... the company’s online market share by a series of promotions. ... and announced a bridesmaid dress promotion for the new year ... All the dresses from this company are not only of ... is very good at manufacturing wedding dresses. Customers prefer to ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 2Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 3Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 4Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 5Health News:Zane Benefits, Inc. Announces New Webinar on The End of Employer-Provided Health Insurance Now Available On-Demand! 2Health News:Customers Are Welcome to Shop at PrettyTailor.com 2Health News:Trendy Bamboo Mats Online Now By BambooFlooringChina.com 2Health News:Bridesmaid Dresses Introduced by Famous Company Discount-Dress.com For The New Year 2015 2
... some of the biggest health problems facing the UK ... Research Council (EPSRC) , The projects focus on developing ... issues such as cancer, stroke, AIDS, influenza, MRSA and ... given by the EPSRC, acting as the lead Research ...
... NJHA Members Gain Insight into nTelagent,s SPMS, the ... Serve Self-Pay Patients, Improve Upfront Revenue Cycle Processes, ... 12 Across the state of New Jersey, ... of the sagging economy - from mounting bad ...
... or the "Company") (NASDAQ: TTHI , TSX: TTH) ... at 4:30 P.M. EST to discuss the Third Quarter fiscal ... Officer of the Company, will host the call. Transition will ... release to be issued prior to the call. In order ...
... the side effects of surgeryNEW YORK, May 12 ... Radiology at: http://inr.mediaseed.tv/SIR_36322/ ... treatment -- focal cryoablation that freezes prostate tumors ... the side effects of sexual and urinary dysfunction. ...
... Wii(TM) Fitness Title and All-New Portable Nintendo DS(TM) Game ... This Fall, gamers will be able to work out ... home or on the go. Majesco Entertainment Company (Nasdaq: ... games for the mass market, and executive producer Interactive ...
... Institute Says Aflac Among Top 50 Reputable Companies Around ... today announced that it was named the most reputable ... a row, by Reputation Institute . Aflac edged out ... 2009 Global Reputation Pulse study of the most reputable companies ...
Cached Medicine News:Health News:$24.4 million for research into future health care solutions 2Health News:New Jersey Hospital Association to Promote nTelagent's Self-Pay Management System 2Health News:New Jersey Hospital Association to Promote nTelagent's Self-Pay Management System 3Health News:Transition Therapeutics to Hold Conference Call on Third Quarter Fiscal 2009 Financial Results on Wednesday, May 13th, at 4:30 P.M. EST 2Health News:VIDEO from Medialink and the Society of Interventional Radiology: Prostate and Kidney Cancer - New Life-Changing Developments 2Health News:Majesco Entertainment and Interactive Game Group Announce Two New Jillian Michaels Fitness Video Games 2Health News:Majesco Entertainment and Interactive Game Group Announce Two New Jillian Michaels Fitness Video Games 3Health News:Majesco Entertainment and Interactive Game Group Announce Two New Jillian Michaels Fitness Video Games 4Health News:Majesco Entertainment and Interactive Game Group Announce Two New Jillian Michaels Fitness Video Games 5Health News:Aflac Tops the Global Insurance Industry for Reputation 2Health News:Aflac Tops the Global Insurance Industry for Reputation 3
Compressor-cooled plate used to keep blocks cold while sectioning....
... CO-Oximeter Control (Bayer 800 Series) is ... monitoring the performance of blood gas, ... 270 and 800 series) instrumentation. This ... Bayer 800 Rapidlab Series instruments in ...
Liquichek Blood Gas Plus CO-Oximeter Control (IL Synthesis Series) is a combination control for use in monitoring the performance of blood gas, ion-selective electrode, biosensor and CO-Oximetry anal...
Liquichek Blood Gas Plus E Control is an aqueous product used to monitor the measurement of pH, pCO2, pO2 and electrolytes. Available in four levels....
Medicine Products: